Literature DB >> 269743

[Extracorporeal treatment with L-asparaginase (author's transl)].

H Pralle, H Löffler.   

Abstract

L-asparaginase therapy is often limited by allergy or toxicity and probably in some cases by antibody mediated inactivation of the enzyme. These problems can be avoided by extracorporeal application of l-asparaginase. As the enzyme is a stable tetramer with high molecular weight it cannot pass through the dialysis membrane in contrast to the amino acid l-asparagin which is destroyed. The resulting l-asparagin depletion of the plasma is sufficient for therapeutic success. Effective extracorporeal l-asparaginase therapy is demonstrated in two patients with ALL who were resistant to other chemotherapy and could not be treated intravenously because of allergy and toxicity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 269743     DOI: 10.1007/bf00999458

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  24 in total

1.  Basis for loss of therapeutic effectiveness of L-asparaginase in sensitized mice.

Authors:  S Baechtel; M D Prager
Journal:  Cancer Res       Date:  1973-08       Impact factor: 12.701

2.  [Therapy of acute leukemias in children. 1].

Authors:  C Jacquillat; M Weil; G Schaison; J Delobel; A Bussel; R Brunel-Kotschi; M F Gemon; J P Loisel
Journal:  Med Klin       Date:  1972-08-04

3.  [On the biochemistry of asparginase].

Authors:  K Bauer
Journal:  Med Klin       Date:  1969-01-03

4.  The liver damaging effect of L-asparaginase--an experimental study of chronic toxicity.

Authors:  G Celle; M Dodero; I Pannacciulli
Journal:  Eur J Cancer       Date:  1973-01       Impact factor: 9.162

5.  Transient diabetes mellitus secondary to L-asparaginase therapy in acute leukemia.

Authors:  P C Gillette; L L Hill; K A Starling; D J Fernbach
Journal:  J Pediatr       Date:  1972-07       Impact factor: 4.406

6.  Drug dosage and remission duration in childhood lymphocytic leukemia.

Authors:  D Pinkel; K Hernandez; L Borella; C Holton; R Aur; G Samoy; C Pratt
Journal:  Cancer       Date:  1971-02       Impact factor: 6.860

7.  Result of a cooperative study with L-asparaginase in human leukemias. Report of the section "oncology" of the Paul-Ehrlich-Society for Chemotherapy.

Authors:  H Gerhartz; H Begemann
Journal:  Recent Results Cancer Res       Date:  1970

8.  Letter: Toxicity of asparaginases.

Authors:  D A Rutter
Journal:  Lancet       Date:  1975-06-07       Impact factor: 79.321

9.  L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia.

Authors:  J A Ortega; M E Nesbit; M H Donaldson; R E Hittle; J Weiner; M Karon; D Hammond
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

10.  Evidence that the L-asparaginase of guinea pig serum is responsible for its antilymphoma effects. I. Properties of the L-asparaginase of guinea pig serum in relation to those of the antilymphoma substance.

Authors:  J D BROOME
Journal:  J Exp Med       Date:  1963-07       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.